- Home
- BSX
as 02-21-2025 12:33pm EST
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | MARLBOROUGH |
| Market Cap: | 129.7B | IPO Year: | 1992 |
| Target Price: | $107.23 | AVG Volume (30 days): | 6.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.25 | EPS Growth: | 16.82 |
| 52 Week Low/High: | $65.52 - $107.17 | Next Earning Date: | 02-05-2025 |
| Revenue: | $16,747,000,000 | Revenue Growth: | 17.61% |
| Revenue Growth (this year): | 13.4% | Revenue Growth (next year): | 10.23% |
Stock Insider Trading Activity of Boston Scientific Corporation (BSX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mirviss Jeffrey B. | BSX | EVP&Pres, Periph Intervent | Feb 19 '25 | Sell | $105.35 | 1,510 | $159,078.50 | 33,129 | |
| Brennan Daniel J. | BSX | EVP and CFO | Feb 18 '25 | Sell | $104.66 | 84,863 | $8,919,295.52 | 232,618 | |
| Sorenson John Bradley | BSX | EVP, Global Operations | Feb 18 '25 | Sell | $104.80 | 5,960 | $624,860.60 | 20,991 | |
| Sorenson John Bradley | BSX | EVP, Global Operations | Feb 13 '25 | Sell | $106.31 | 1,201 | $127,678.31 | 20,991 | |
| LUDWIG EDWARD J | BSX | Director | Feb 11 '25 | Sell | $105.48 | 12,000 | $1,265,815.20 | 24,398 | |
| Brennan Daniel J. | BSX | EVP and CFO | Feb 11 '25 | Sell | $105.07 | 15,087 | $1,585,135.27 | 232,618 | |
| Sorenson John Bradley | BSX | EVP, Global Operations | Feb 7 '25 | Sell | $104.97 | 6,528 | $685,244.16 | 20,991 | |
| Butcher Arthur C | BSX | EVP& Grp Pres, MedSurg & APAC | Feb 3 '25 | Sell | $101.80 | 17,313 | $1,762,507.23 | 5,502 | |
| Brennan Daniel J. | BSX | EVP and CFO | Jan 1 '25 | Sell | $89.86 | 9,689 | $870,636.10 | 232,618 | |
| Mirviss Jeffrey B. | BSX | EVP&Pres, Periph Intervent | Jan 1 '25 | Sell | $89.86 | 7,152 | $642,657.98 | 33,129 |
Latest Boston Scientific Corporation News
BSX Breaking Stock News: Dive into BSX Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Boston Scientific Expects Strong Gains in 2025: Time to Buy the Stock?
MT Newswires
2 days ago
Boston Scientific Insider Sold Shares Worth $8,919,296, According to a Recent SEC Filing
MT Newswires
2 days ago
Boston Scientific Insider Sold Shares Worth $624,861, According to a Recent SEC Filing
Insider Monkey
2 days ago
Solid Company Fundamentals Lifted Boston Scientific Corporation (BSX)
StockStory
2 days ago
Baxter Earnings: What To Look For From BAX
PR Newswire
2 days ago
Boston Scientific to participate in TD Cowen's 45th Annual Health Care Conference
Zacks
2 days ago
Is it the Right Time to Hold EYE Stock in Your Portfolio Now?
MT Newswires
3 days ago
Argus Research Adjusts Price Target on Boston Scientific to $130 From $105
Compare BSX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BSX Boston Scientific Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.